Needham & Company Raises Aegerion Pharmaceuticals (AEGR) Price Target to $30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Jefferies Boosts Price Target on Aegerion (AEGR) after Positive FDA Panel
October 18, 2012 3:33 PM EDTJefferies raised its price target on Aegerion Pharmaceuticals (NASDAQ: AEGR) from $20 to $22 after FDA panel backing.
"FDA's panel voted 13-2 for recommending approval of lomitapide. Focus now is on the # of eligible patient population & commercial opportunity. Panel discussion did not clearly define #... More
Aegerion (AEGR) Wins FDA Approval of Lomitapide in Lowering Cholesterol with HoFH Patients
October 17, 2012 3:52 PM EDTAegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), said to win FDA approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with Homozygous Familial Hypercholesterolemia (HoFH).... More
Aegerion (AEGR) Trading Halted Ahead of Lomitapide FDA Committee Meeting
October 17, 2012 7:06 AM EDTAegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced that NASDAQ has halted trading of the company's common stock today. The Endocrinologic and Metabolic Drugs... More
